US biotech company ArQule said a monitoring committee raised concerns about dosing level and the safety of a liver cancer therapy the drug maker is testing with partner Daiichi Sankyo.
The Data Monitoring Committee recommended that dosing of the drug tivantinib be reduced from 240 milligrams twice daily to 120...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

